Core Insights - Akero Therapeutics, Inc. is set to present significant findings related to its lead product candidate, efruxifermin (EFX), at the EASL Congress 2025, highlighting advancements in treating metabolic diseases with high unmet medical needs [1][3]. Presentation Details - The first oral presentation will focus on the results of a 96-week, randomized, double-blind, placebo-controlled Phase 2b trial (SYMMETRY) demonstrating that efruxifermin improves fibrosis in participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) [2]. - The second oral presentation will discuss the alignment of non-invasive fibrosis biomarkers and AI-based histology assessments in MASH clinical trials, providing a new roadmap for drug efficacy evaluation as demonstrated in the HARMONY trial [2]. - A poster presentation will showcase how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients with F2-F3 MASH in the 96-week HARMONY study [3]. Company Overview - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, particularly MASH, with efruxifermin being evaluated in three ongoing Phase 3 clinical studies [3]. - The Phase 3 SYNCHRONY program builds on the results from two Phase 2b trials, the HARMONY study and the SYMMETRY study, indicating a robust pipeline for addressing metabolic diseases [3].